当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Flucelvax Quadrivalent, Influenza Vaccine
药品名称
Flucelvax Quadrivalent, Influenza Vaccine
承诺描述
Deferred pediatric dose ranging, immunogenicity and safety study (Study V58P16) under PREA in children ages 6 months to less than 4 years.
承诺状态描述
Per FDA letter dated March 3, 2021, this PMR has been released.